Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Summary of the HTA, funding and innovation payment landscape for cardiovascular devices in Europe

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including cardiovascular technologies.

Did you know that:

  • There were 24 health technology assessments of cardiovascular technologies in 2018 in Europe;
  • These assessments were published only in 7 EU countries;
  • Only five assessments were published by the regional HTA bodies, the remaining were published by the national organizations;
  • There were 33 funding decisions about cardiovascular technologies published in 4 EU with established funding frameworks countries for all time periods;
  • In 67% of the cases, funding decisions were positive in relation to cardiovascular technologies;
  • There were 14 positive innovation funding decisions (NUB) for cardiovascular technologies in Germany in 2019.

By accessing one or several of our syndicated reports you can:

  • Understand the relevance of topics of innovation funding, health technology assessment and funding frameworks in the cardiovascular field;
  • Understand, which countries are more active with HTA, funding and innovation funding for cardiovascular devices;
  • Understand, what types of technologies typically triggers HTA or review by the funding authorities / decision-makers;
  • Understand, what cardiovascular technologies got positive and negative funding decisions;
  • Develop fact-based market access strategies for your portfolio of devices;
  • Prioritize markets, based on the solid information about HTA and reimbursement activity for your type of product.

You can get access either to the full reports or limited to the topic of cardiovascular devices. Download sample pages of the reports via the links provided above.

Contact us at to request a quote or get more information.